SLU-PP-332 vs Sermorelin
Side-by-side comparison of key properties, dosing, and research.
Recovery & RepairFat Loss & Metabolic
SLU-PP-332Growth Hormone PeptidesAnti-Aging & Longevity
Sermorelin- Summary
- SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
- Sermorelin is a bioidentical synthetic peptide comprising the first 29 amino acids of naturally occurring GHRH. It is FDA-approved for diagnostic use and widely prescribed off-label for anti-aging, stimulating growth hormone production in a natural pulsatile pattern that mimics the body's own rhythm.
- Half-Life
- Not established in humans; rodent pharmacokinetics suggest hours
- 10–20 minutes
- Admin Route
- Oral (research), Subcutaneous (research)
- SubQ
- Research
- —
- —
- Typical Dose
- Not established for humans; rodent studies used ~100 mg/kg/day
- 200–500 mcg
- Frequency
- Once daily in rodent studies
- 5–7 days per week
- Key Benefits
- Significant enhancement of aerobic endurance capacity
- Increases mitochondrial density and oxidative metabolism in muscle
- Promotes beneficial shift toward oxidative muscle fiber phenotype
- Improves cardiac efficiency and cardiovascular fitness markers
- Potential for obesity, metabolic syndrome, and heart failure treatment
- Exercise mimetic for populations unable to exercise (disability, frailty, disease)
- Increases energy and vitality
- Improves body composition (more muscle, less fat)
- Enhances skin thickness and elasticity
- Strengthens immune system
- Improves sleep quality and REM sleep
- Supports bone density
- Enhances mental clarity and focus
- Safer than exogenous HGH — respects natural feedback loops
- FDA-approved for GH diagnostic use
- Side Effects
- Limited human data; all studies are preclinical (rodent)
- Unknown cardiovascular effects with long-term or high-dose use in humans
- Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
- Off-target effects not fully characterized
- Injection site irritation
- Flushing
- Headache
- Dizziness
- +2 more
- Stacks With
- —
- —